How many Selinexor clinical trials are there?

181 Selinexor clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 43 are marked completed.

Are Selinexor clinical trials recruiting in 2026?

Yes — 40 Selinexor trials are actively recruiting in 2026, with 226 U.S. sites across 42 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Selinexor being studied for?

Selinexor is being studied for Multiple Myeloma, Acute Myeloid Leukemia, Refractory Multiple Myeloma, Myelofibrosis, Endometrial Cancer and 281 more. The trials are grouped by indication on this page.

What phase is Selinexor in?

Selinexor clinical trials span 1 Phase 4, 15 Phase 3, 76 Phase 2, 36 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Selinexor clinical trials?

The lead sponsor across the most Selinexor trials is Karyopharm Therapeutics Inc, with 98 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Selinexor Clinical Trials (2026): 181 Studies for Multiple Myeloma & Acute Myeloid Leukemia

Creator: Hipa.ai Research
Published: 2026-05-14T21:43:58.184Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

181 Selinexor clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 118 indications (including Multiple Myeloma & Acute Myeloid Leukemia) and 12,715 total planned enrollment. 15 Phase 3 Selinexor trials and 76 Phase 2, 1 Phase 4 are listed. 55 Selinexor clinical trials are actively recruiting at 226 U.S. sites across 42 states. Most recent activity: NCT06239272 (Jun 2037).

Where to Participate: All Selinexor Trial Sites in the U.S. (226 sites across 42 states)

Every actively recruiting Selinexortrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Children's Hospital of Alabama	Birmingham35233	NCT05099003	Map
AL	University of Alabama at Birmingham - Main /ID# 261434	Birmingham35233	NCT06158841	Map
AZ	Banner Children's at Desert	Mesa85202	NCT05099003	Map
AZ	Mayo Clinic Hospital - Phoenix /ID# 263326	Phoenix85054	NCT06158841	Map
AZ	Mayo Clinic Hospital in Arizona	Phoenix85054	NCT05432804	Map
AZ	Phoenix Childrens Hospital	Phoenix85016	NCT05099003	Map
AR	Arkansas Children's Hospital	Little Rock72202-3591	NCT05099003	Map
CA	City of Hope - Duarte Main Site	Duarte91010	NCT05980806	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT05432804	Map
CA	Providence - St. Jude Medical Center /ID# 262031	Fullerton92835	NCT06158841	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT05432804	Map
CA	Loma Linda University Medical Center	Loma Linda92354	NCT05099003	Map
CA	VA Loma Linda Healthcare System /ID# 261015	Loma Linda92357	NCT06158841	Map
CA	Miller Children's and Women's Hospital Long Beach	Long Beach90806	NCT05099003	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT05099003	Map
CA	Cedars-Sinai Medical Center /ID# 261008	Los Angeles90048	NCT06158841	Map
CA	Children's Hospital Los Angeles	Los Angeles90027	NCT05099003	Map
CA	Children's Hospital of Los Angeles (Data Collection Only)	Los Angeles90027	NCT05985161	Map
CA	Keck Medicine of USC Koreatown	Los Angeles90020	NCT05333458	Map
CA	Keck Medicine of USC Koreatown	Los Angeles90020	NCT05432804	Map
CA	Los Angeles General Medical Center	Los Angeles90033	NCT05432804	Map
CA	USC / Norris Comprehensive Cancer Center	Los Angeles90033	NCT05432804	Map
CA	Kaiser Permanente-Oakland	Oakland94611	NCT05099003	Map
CA	UCSF Benioff Children's Hospital Oakland	Oakland94609	NCT05099003	Map
CA	Children's Hospital of Orange County	Orange92868	NCT05099003	Map
CA	Lucile Packard Children's Hospital Stanford University	Palo Alto94304	NCT05099003	Map
CA	Stanford Medicine Children's Health (Data Collection Only)	Palo Alto94304	NCT05985161	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT05432804	Map
CA	Rady Children's Hospital - San Diego	San Diego92123	NCT05099003	Map
CA	UCSF Medical Center-Mission Bay	San Francisco94158	NCT05099003	Map
CA	Berenson Cancer Center	West Hollywood90069	NCT06225310	Map
CO	Children's Hospital Colorado	Aurora80045	NCT05099003	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT05432804	Map
CO	Rocky Mountain Cancer Centers - Lone Tree /ID# 278320	Lone Tree80124	NCT06158841	Map
CT	Connecticut Children's Medical Center	Hartford06106	NCT05099003	Map
CT	Yale University	New Haven06520	NCT05099003	Map
CT	Yale University	New Haven06520	NCT05333458	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT05333458	Map
DE	Alfred I duPont Hospital for Children	Wilmington19803	NCT05099003	Map
DC	Children's National Hospital (Data Collection Only)	Washington D.C.20010	NCT05985161	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05099003	Map
DC	MedStar Georgetown University Hospital	Washington D.C.20007	NCT05333458	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT05432804	Map
FL	University of Miami, Lennar Foundation Medical Center	Coral Gables33146	NCT05530421	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT05432804	Map
FL	University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT05530421	Map
FL	Golisano Children's Hospital of Southwest Florida	Fort Myers33908	NCT05099003	Map
FL	Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230	Jacksonville32256	NCT06158841	Map
FL	Mayo Clinic Hospital Jacksonville /ID# 263324	Jacksonville32224	NCT06158841	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT05432804	Map
FL	Nemours Children's Clinic-Jacksonville	Jacksonville32207	NCT05099003	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT05099003	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT05432804	Map
FL	University of Miami, Sylvester Comprehensive Cancer Center	Miami33136	NCT05530421	Map
FL	Arnold Palmer Hospital for Children	Orlando32806	NCT05099003	Map
FL	Nemours Children's Hospital	Orlando32827	NCT05099003	Map
FL	Johns Hopkins All Children's Hospital	St. Petersburg33701	NCT05099003	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05432804	Map
FL	Saint Joseph's Hospital/Children's Hospital-Tampa	Tampa33607	NCT05099003	Map
GA	Children's Healthcare of Atlanta - Arthur M Blank Hospital	Atlanta30329	NCT05099003	Map
GA	Children's Healthcare of Atlanta (Data Collection and Specimen Analysis)	Atlanta30322	NCT05985161	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT05432804	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05432804	Map
GA	Winship Cancer Institute of Emory University /ID# 262525	Atlanta30322	NCT06158841	Map
HI	Kapiolani Medical Center for Women and Children	Honolulu96826	NCT05099003	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT05099003	Map
IL	Ann & Robert H. Lurie Children'S Hospital of Chicag	Chicago60611	NCT05985161	Map
IL	Lurie Children's Hospital of Chicago	Chicago60611	NCT06239272	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05099003	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05432804	Map
IL	University of Illinois Hospital and Health Sciences System /ID# 246349	Chicago60607	NCT06158841	Map
IL	Nancy W. Knowles Cancer Center /ID# 271361	Elmhurst60126	NCT06158841	Map
IL	Loyola University Medical Center	Maywood60153	NCT05983276	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT05432804	Map
IL	OSF Children's Hospital of Illinois	Peoria61637	NCT05099003	Map
IL	Springfield Clinic - First /ID# 262266	Springfield62702	NCT06158841	Map
IN	Riley Hospital for Children	Indianapolis46202	NCT05099003	Map
IA	Blank Children's Hospital	Des Moines50309	NCT05099003	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT05099003	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT05099003	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT05432804	Map
KY	Norton Children's Hospital	Louisville40202	NCT05099003	Map
LA	Our Lady of the Lake Children's Hospital	Baton Rouge70809	NCT06239272	Map
LA	Our Lady Of The Lake Regional Medical Center /ID# 272780	Baton Rouge70808	NCT06158841	Map
LA	Children's Hospital New Orleans	New Orleans70118	NCT05099003	Map
ME	Eastern Maine Medical Center	Bangor04401	NCT05099003	Map
ME	Maine Children's Cancer Program	Scarborough04074	NCT05099003	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT05099003	Map
MD	Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637	Bethesda20817	NCT06158841	Map
MD	National Cancer Institute Developmental Therapeutics Clinic	Bethesda20892	NCT05333458	Map
MD	Maryland Oncology Hematology - Independent of SCRI/ US Oncology	Columbia21044	NCT05980806	Map
MA	Beth Israel Deaconess Medical Center /ID# 271535	Boston02215	NCT06158841	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06239272	Map
MA	Dana Farber Cancer Institute (Data Collection Only)	Boston02115	NCT05985161	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05099003	Map
MA	Dana-Farber Cancer Institute /ID# 261554	Boston02215	NCT06158841	Map
MI	C S Mott Children's Hospital	Ann Arbor48109	NCT05099003	Map
MI	Regents of the University of Michigan /ID# 261577	Ann Arbor48109-1276	NCT06158841	Map
MI	Children's Hospital of Michigan	Detroit48201	NCT05099003	Map
MI	Karmanos Cancer Institute - Detroit /ID# 266298	Detroit48201	NCT06158841	Map
MI	Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital	Grand Rapids49503	NCT05099003	Map
MI	Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891	Lansing48912	NCT06158841	Map
MN	Children's Hospitals and Clinics of Minnesota - Minneapolis	Minneapolis55404	NCT05099003	Map
MN	University of Minnesota/Masonic Cancer Center	Minneapolis55455	NCT05099003	Map
MN	Mayo Clinic - Rochester /ID# 246228	Rochester55905-0001	NCT06158841	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05432804	Map
MS	University of Mississippi Medical Center	Jackson39216	NCT05099003	Map
MO	Children's Mercy Hospitals and Clinics	Kansas City64108	NCT05099003	Map
MO	Cardinal Glennon Children's Medical Center	St Louis63104	NCT05099003	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT05099003	Map
MO	Washington University	St Louis63110	NCT05985161	Map
MO	Washington University Medical Center	St Louis63110	NCT06239272	Map
MO	Washington University School of Medicine	St Louis63110	NCT05099003	Map
MO	Washington University School of Medicine	St Louis63110	NCT07200102	Map
NE	Children's Hospital and Medical Center of Omaha	Omaha68114	NCT05099003	Map
NE	Nebraska Cancer Specialists - Omaha - Wright Street /ID# 276772	Omaha68130	NCT06158841	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT05099003	Map
NJ	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT05985161	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT05099003	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT05432804	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT05985161	Map
NJ	Memorial Sloan Kettering Bergen (Limited protocol activities)	Montvale07645	NCT05985161	Map
NJ	Morristown Medical Center	Morristown07960	NCT05099003	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05432804	Map
NJ	Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital	New Brunswick08903	NCT05099003	Map
NJ	Newark Beth Israel Medical Center	Newark07112	NCT05099003	Map
NJ	Rutgers New Jersey Medical School	Newark07101	NCT05432804	Map
NJ	Saint Joseph's Regional Medical Center	Paterson07503	NCT05099003	Map
NY	Albany Medical Center	Albany12208	NCT05099003	Map
NY	New York Cancer & Blood Specialists - Bay Shore /ID# 261524	Bay Shore11706	NCT06158841	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT05099003	Map
NY	Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )	Commack11725	NCT05985161	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT05985161	Map
NY	The Steven and Alexandra Cohen Children's Medical Center of New York	New Hyde Park11040	NCT05099003	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York10016	NCT05099003	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York10016	NCT05432804	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05099003	Map
NY	Memorial Sloan Kettering Cancer Center (All protocol activites)	New York10065	NCT05985161	Map
NY	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York10032	NCT05099003	Map
NY	Weill Cornell Medicine NewYork-Presbyterian	New York10021	NCT05980806	Map
NY	University of Rochester	Rochester14642	NCT05597345	Map
NY	Memorial Sloan Kettering Nassau (Limited protocol activities)	Rockville Centre11553	NCT05985161	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT05099003	Map
NY	Eastchester Center for Cancer Care /ID# 262952	The Bronx10469	NCT06158841	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT05099003	Map
NC	University of North Carolina /ID# 259854	Chapel Hill27514	NCT06158841	Map
NC	Atrium Health Levine Cancer Institute /ID# 246199	Charlotte28204	NCT06158841	Map
NC	Novant Health Presbyterian Medical Center	Charlotte28204	NCT05099003	Map
NC	Duke University	Durham27705	NCT05980806	Map
NC	Duke University Health System	Durham27705	NCT06822972	Map
NC	East Carolina University	Greenville27834	NCT05099003	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05099003	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05432804	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT05099003	Map
OH	Children's Hospital Medical Center of Akron	Akron44308	NCT05099003	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05099003	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT06239272	Map
OH	Cincinnati Children's Hospital Medical Center (Data collection only)	Cincinnati45229	NCT05985161	Map
OH	University of Cincinnati Cancer Center-UC Medical Center	Cincinnati45219	NCT05432804	Map
OH	University Of Cincinnati Medical Center /ID# 246415	Cincinnati45219	NCT06158841	Map
OH	Cleveland Clinic	Cleveland44195	NCT05980806	Map
OH	Cleveland Clinic Main Campus /ID# 246183	Cleveland44195	NCT06158841	Map
OH	Rainbow Babies and Childrens Hospital	Cleveland44106	NCT05099003	Map
OH	Nationwide Children's Hospital	Columbus43205	NCT05099003	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05333458	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05432804	Map
OH	Dayton Children's Hospital	Dayton45404	NCT05099003	Map
OH	ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital	Toledo43606	NCT05099003	Map
OH	University of Cincinnati Cancer Center-West Chester	West Chester45069	NCT05432804	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05099003	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05333458	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05432804	Map
OR	Legacy Emanuel Children's Hospital	Portland97227	NCT05099003	Map
OR	Oregon Health and Science University	Portland97239	NCT05099003	Map
OR	Oregon Medical Research Center /ID# 262335	Portland97239	NCT06158841	Map
PA	Geisinger Medical Center	Danville17822	NCT05099003	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT05099003	Map
PA	Saint Christopher's Hospital for Children	Philadelphia19134	NCT05099003	Map
PA	Children's Hospital of Pittsburgh of UPMC	Pittsburgh15224	NCT05099003	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT05333458	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT05432804	Map
RI	Rhode Island Hospital	Providence02903	NCT05099003	Map
SC	Medical University of South Carolina /ID# 259692	Charleston29425	NCT06158841	Map
SC	Prisma Health Richland Hospital	Columbia29203	NCT05099003	Map
SC	BI-LO Charities Children's Cancer Center	Greenville29605	NCT05099003	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT05099003	Map
TN	East Tennessee Childrens Hospital	Knoxville37916	NCT05099003	Map
TN	Baptist Memorial Hospital /ID# 270910	Memphis38120	NCT06158841	Map
TN	Saint Jude Children's Research Hospital	Memphis38105	NCT05099003	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT06239272	Map
TN	The West Clinic /ID# 262444	Memphis38120	NCT06158841	Map
TN	University of Tennessee Health Science Center /ID# 261622	Memphis38103	NCT06158841	Map
TN	The Children's Hospital at TriStar Centennial	Nashville37203	NCT05099003	Map
TN	Vanderbilt University Medical Center /ID# 261621	Nashville37232-0011	NCT06158841	Map
TX	Dell Children's Medical Center of Central Texas	Austin78723	NCT05099003	Map
TX	Driscoll Children's Hospital	Corpus Christi78411	NCT05099003	Map
TX	Medical City Dallas Hospital	Dallas75230	NCT05099003	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT05099003	Map
TX	El Paso Children's Hospital	El Paso79905	NCT05099003	Map
TX	Cook Children's Health Care System (Data Collection Only)	Fort Worth76104	NCT05985161	Map
TX	Cook Children's Medical Center	Fort Worth76104	NCT05099003	Map
TX	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston77030	NCT05099003	Map
TX	MD Anderson	Houston77030	NCT05980806	Map
TX	Oncology Consultants /ID# 276774	Houston77030	NCT06158841	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05099003	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05333458	Map
TX	Children's Hospital of San Antonio	San Antonio78207	NCT05099003	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT05099003	Map
TX	Texas Oncology - Northeast Texas /ID# 278304	Tyler75702	NCT06158841	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT05980806	Map
UT	Primary Children's Hospital	Salt Lake City84113	NCT05099003	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT05099003	Map
VA	Virginia Cancer Specialists - Fairfax /ID# 262792	Fairfax22031	NCT06158841	Map
VA	Children's Hospital of The King's Daughters	Norfolk23507	NCT05099003	Map
VA	Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 278314	Norfolk23502	NCT06158841	Map
VA	VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 261944	Richmond23298	NCT06158841	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT05432804	Map
WA	Seattle Children's Hospital	Seattle98105	NCT05099003	Map
WA	Providence Sacred Heart Medical Center and Children's Hospital	Spokane99204	NCT05099003	Map
WA	Mary Bridge Children's Hospital and Health Center	Tacoma98405	NCT05099003	Map
WA	Northwest Medical Specialties Tacoma /ID# 276281	Tacoma98405	NCT06158841	Map
WI	University of Wisconsin	Madison53705	NCT07479979	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT05432804	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05099003	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05432804	Map
WI	Children's Hospital of Wisconsin	Milwaukee53226	NCT05099003	Map

Selinexor clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	no longer available	available	Total
Early P1						1						1
P1	2	3		21	4	2			4			36
P1/P2	12	3		7	4	5			5			36
P2	15	12	1	10	13	5	1	13	6			76
P2/P3	1	1		1					1			4
P3	5	4		3	1			2				15
P4									1			1
N/A	4	2		1					3	1	1	12

Recruiting Selinexor clinical trials (55)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06239272	NRSTSNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)	P1/P2	Adipocytic Neoplasm	139	Mar 2024
NCT05983276	Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer	P2	Ovarian Cancer	40	Nov 2023
NCT07574528	A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma	P2	NKTCL	47	May 2026
NCT07200102	Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma	P1	Multiple Myeloma	20	Mar 2026
NCT07569757	Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma	P3	Multiple Myeloma	260	Jun 2026
NCT07447817	Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias	P2	Myelofibrosis	26	May 2026
NCT05530421	SELVEDgeSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma	P2	Relapsed and Refractory Multiple Myeloma	33	Mar 2023
NCT06744894	SIL as Maintenance Therapy in Multiple Myeloma	P2	Multiple Myeloma	50	Jan 2025
NCT07138209	A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma	P3	Relapsed or Refractory Multiple Myeloma	228	Nov 2025
NCT07276698	Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma	P2	NK T-Cell Lymphoma	39	Dec 2025
NCT07191431	SELINAA Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）	N/A	Lymphoma Cns	25	Sep 2025
NCT05985161	A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	P2	Wilms Tumor	45	Aug 2023
NCT07479979	Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma	P1/P2	Relapse Multiple Myeloma	62	Jul 2026
NCT07011056	A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma	P3	Recurrent and Refractory Diffuse Large B-cell Lymphoma	390	Jul 2025
NCT07554482	Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma	P2	Extranodal NK/T-cell Lymphoma	34	May 2026
NCT07579234	A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma	P3	Relapsed or Refractory Multiple Myeloma (RRMM)	261	Jan 2026
NCT07172412	Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer	P2	Extensive Stage Lung Small Cell Cancer	165	Nov 2025
NCT07002099	Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study	P2	Lymphomas	26	Jun 2025
NCT07405255	ZillionZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma	P2	Central Nervous System Lymphoma	19	Jan 2026
NCT06552559	SIENASelinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	P1/P2	B-cell Lymphoma Recurrent	37	May 2024
NCT06652139	Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive	P2	Diffuse Large B Cell Lymphoma	82	Nov 2024
NCT05980806	SENTRY-2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia	P2	Myelofibrosis	58	Apr 2024
NCT06556199	A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma	P1/P2	Relapsed/Refractory Primary Central Nervous System Lymphoma	38	Aug 2024
NCT05675813	THEORYGenotype-guided Treatment in Newly Diagnosed PTCL	P1/P2	Peripheral T Cell Lymphoma	264	Feb 2023
NCT06966154	A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	P1/P2	Natural Killer/T-cell Lymphoma	68	May 2025
NCT06517511	Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)	P2	Diffuse Large B Cell Lymphoma	42	Aug 2024
NCT06813079	Using Tumor Models to Determine Treatments	P2	Pancreatic Ductal Carcinoma	25	Feb 2025
NCT04414475	LDDA Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.	P2	Multiple Myeloma, Refractory	127	Jul 2020
NCT07369739	Golidocitinib Combined With Selinexor for CAEBVD	P2/P3	Lymphohistiocytosis	28	Jan 2026
NCT06765928	Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT	P2	MDS	73	Jan 2025
NCT06822972	HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM	P2	Multiple Myeloma in Relapse	27	Aug 2025
NCT06158841	CERVINOStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma	P3	Multiple Myeloma	380	May 2024
NCT05035745	STARTSelinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)	P1/P2	Advanced Refractory Solid Tumors	63	Mar 2021
NCT06613035	Twice-per-weekSelinexor, 2 Days Melphalan	P3	Acute Myeloid Leukemia	126	Sep 2024
NCT06573151	Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL	P2	Lymphoma	28	Sep 2024
NCT06573138	Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL	P2	Lymphoma, Extranodal NK-T-Cell	18	Sep 2024
NCT05432804	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	P1/P2	Recurrent Glioblastoma, IDH-Wildtype	97	Mar 2023
NCT05099003	DIPGA Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	P1/P2	Malignant Glioma	132	May 2022
NCT06225310	KPT-IST-391A Trial of Selinexor, Ruxolitinib and Methylprednisolone	P1	Multiple Myeloma in Relapse	30	Aug 2024
NCT05333458	Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial	P2	Advanced Alveolar Soft Part Sarcoma	27	Aug 2022
NCT07514052	Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study	—	Multiple Myeloma of Bone	127	Jan 2026
NCT05736965	SAVA Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia	P2	AML, Adult	58	Feb 2023
NCT05736978	AVSAdaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results	P2	AML	58	Mar 2023
NCT06853678	Second-line Immunotherapy for ES-SCLC	N/A	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	30	Feb 2025
NCT06559553	Selinexor"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL	P1/P2	NKTCL	50	Sep 2024
NCT05698147	Selinexor in Combination With MTX+Ritu to Treat R/R CNSL	P1/P2	Central Nervous System Lymphoma	30	Aug 2023
NCT06900088	Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients	P2	Acute Myeloid Leukemia	20	Apr 2025
NCT06664970	A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor	P2	MDS	39	Nov 2024
NCT06265545	Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia	N/A	AML	120	Feb 2024
NCT06114004	SeliSarcSelinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)	P2	Sarcoma,Soft Tissue	88	Sep 2023
NCT05597345	Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma	P2	Smoldering Multiple Myeloma	15	Aug 2023
NCT05422066	Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma	P2	DLBCL Germinal Center B-Cell Type	50	Jul 2022
NCT05422027	Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma	P1/P2	Multiple Myeloma	42	Jul 2022
NCT05900882	SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease	P2	Multiple Myeloma	35	Jul 2022
NCT05726110	Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia	P3	Relapsed or Refractory Acute Myeloid Leukemia	50	Jan 2023

Selinexor clinical trials by indication

Multiple Myeloma (29)

NCT	Acronym	Phase	Status	Title
NCT07200102	—	P1	recruiting	Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07569757	—	P3	not yet recruiting	Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT06744894	—	P2	not yet recruiting	SIL as Maintenance Therapy in Multiple Myeloma
NCT04717700	SABLe	P2	active not recruiting	Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
NCT05028348	—	P3	active not recruiting	A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT06452446	Selinexor	N/A	active not recruiting	Telehealth-based Symptom Management for Veterans Treated With Selinexor
NCT06158841	CERVINO	P3	recruiting	Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT02343042	STOMP	P1/P2	active not recruiting	Selinexor and Backbone Treatments of Multiple Myeloma Patients
+ 21 more, see All trials below.

Acute Myeloid Leukemia (8)

NCT	Acronym	Phase	Status	Title
NCT07437170	—	P2	active not recruiting	Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
NCT06613035	—	P3	not yet recruiting	Twice-per-weekSelinexor, 2 Days Melphalan
NCT06900088	—	P2	not yet recruiting	Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NCT02485535	—	P1	completed	Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
NCT03661515	FLAGINEXOR	P1	completed	Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
NCT02416908	—	P1/P2	completed	Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT02573363	—	P1	completed	Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
NCT02093403	—	P1	completed	Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Myelofibrosis (4)

NCT	Acronym	Phase	Status	Title
NCT07447817	—	P2	not yet recruiting	Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT05980806	SENTRY-2	P2	recruiting	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT04562389	SENTRY	P3	active not recruiting	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562870	—	P2	active not recruiting	A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

Relapsed or Refractory Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT07138209	—	P3	recruiting	A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT04939142	BENCH	P3	active not recruiting	A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06212596	MUKtwelve	P2	completed	Selinexor, Cyclophosphamide and Prednisone in Myeloma

Multiple Myeloma in Relapse (3)

NCT	Acronym	Phase	Status	Title
NCT06822972	—	P2	recruiting	HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
NCT06225310	KPT-IST-391	P1	recruiting	A Trial of Selinexor, Ruxolitinib and Methylprednisolone
NCT04925193	—	P2	active not recruiting	Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT06573151	—	P2	not yet recruiting	Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
NCT02436707	—	P2	active not recruiting	Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT05852028	—	N/A	unknown	A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Refractory Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT03589222	SELIBORDARA	P2	active not recruiting	SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT02199665	SINE	P1	completed	Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT04519476	—	P1	unknown	Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Acute Myeloid Leukemia (AML) (3)

NCT	Acronym	Phase	Status	Title
NCT03071276	—	P2	terminated	Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT02088541	SOPRA	P2	completed	Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT02212561	—	P1	completed	Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NKTCL (2)

NCT	Acronym	Phase	Status	Title
NCT07574528	—	P2	not yet recruiting	A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
NCT06559553	Selinexor	P1/P2	recruiting	"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

Central Nervous System Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT07405255	Zillion	P2	not yet recruiting	Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
NCT05698147	—	P1/P2	recruiting	Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

MDS (2)

NCT	Acronym	Phase	Status	Title
NCT06765928	—	P2	not yet recruiting	Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
NCT06664970	—	P2	enrolling by invitation	A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Diffuse Large B Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT06652139	—	P2	not yet recruiting	Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
NCT06517511	—	P2	recruiting	Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

AML (2)

NCT	Acronym	Phase	Status	Title
NCT05736978	AVS	P2	recruiting	Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT06265545	—	N/A	recruiting	Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05983276	—	P2	recruiting	Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT02269293	KPT-330	P1	completed	Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Sarcoma,Soft Tissue (2)

NCT	Acronym	Phase	Status	Title
NCT06114004	SeliSarc	P2	recruiting	Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
NCT04595994	SeliSarc	P1	unknown	Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Endometrial Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05611931	XPORT-EC-042	P3	active not recruiting	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT03555422	ENGOT-EN5	P3	completed	Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Acute Myeloid Leukemia (Relapsed/Refractory) (2)

NCT	Acronym	Phase	Status	Title
NCT05951855	AML	P2	unknown	Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
NCT02249091	AML	P2	completed	A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Malignant Glioma (2)

NCT	Acronym	Phase	Status	Title
NCT05099003	DIPG	P1/P2	recruiting	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT02323880	—	P1	completed	Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Soft Tissue Sarcoma (2)

NCT	Acronym	Phase	Status	Title
NCT04811196	—	P1	completed	A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
NCT03042819	—	P1	completed	Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Coronavirus Infection (2)

NCT	Acronym	Phase	Status	Title
NCT04349098	Coronavirus	P2	completed	Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
NCT04355676	—	P2	withdrawn	Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Diffuse Large B-cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT02227251	KPT-330	P2	active not recruiting	Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03955783	—	P1	completed	Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Thymoma (2)

NCT	Acronym	Phase	Status	Title
NCT03193437	SELECT	P2	terminated	Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
NCT03466827	TET-SEL	P2	unknown	Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT02403310	—	P1	completed	A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
NCT02530476	SINE	P1/P2	completed	Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Relapse Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT07479979	—	P1/P2	recruiting	Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Extranodal NK/T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07554482	—	P2	not yet recruiting	Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Relapsed or Refractory Multiple Myeloma (RRMM) (1)

NCT	Acronym	Phase	Status	Title
NCT07579234	—	P3	recruiting	A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma of Bone (1)

NCT	Acronym	Phase	Status	Title
NCT07514052	—	N/A	recruiting	Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

Lymphohistiocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT07369739	—	P2/P3	recruiting	Golidocitinib Combined With Selinexor for CAEBVD

NK T-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07276698	—	P2	not yet recruiting	Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Extensive Stage Lung Small Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07172412	—	P2	not yet recruiting	Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Lymphoma Cns (1)

NCT	Acronym	Phase	Status	Title
NCT07191431	SELINA	N/A	recruiting	A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）

Langerhans Cell Histiocytosis (LCH) (1)

NCT	Acronym	Phase	Status	Title
NCT07204041	—	P2	active not recruiting	Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

Recurrent and Refractory Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07011056	—	P3	recruiting	A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Lymphomas (1)

NCT	Acronym	Phase	Status	Title
NCT07002099	—	P2	recruiting	Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

TP53-mutated MDS and AML (1)

NCT	Acronym	Phase	Status	Title
NCT07094464	—	P1	active not recruiting	Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Natural Killer/T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06966154	—	P1/P2	recruiting	A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Extensive Stage Small Cell Lung Cancer (ES-SCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT06853678	—	N/A	recruiting	Second-line Immunotherapy for ES-SCLC

Pancreatic Ductal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06813079	—	P2	not yet recruiting	Using Tumor Models to Determine Treatments

Lymphoma, Extranodal NK-T-Cell (1)

NCT	Acronym	Phase	Status	Title
NCT06573138	—	P2	not yet recruiting	Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Relapsed/Refractory Primary Central Nervous System Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06556199	—	P1/P2	recruiting	A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

B-cell Lymphoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT06552559	SIENA	P1/P2	recruiting	Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Rhabdoid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05952687	—	P1	withdrawn	Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Adipocytic Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT06239272	NRSTS	P1/P2	recruiting	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Extensive-stage Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05975944	—	P1/P2	unknown	Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Smoldering Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05597345	—	P2	recruiting	Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Wilms Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05985161	—	P2	recruiting	A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Lymphoma, Large B-Cell, Diffuse (1)

NCT	Acronym	Phase	Status	Title
NCT05923879	—	N/A	unknown	Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

PTCL Patients Who Achieved Complete Response From Frontline Treatment (1)

NCT	Acronym	Phase	Status	Title
NCT05822050	—	P2/P3	unknown	An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Acute Myeloid Leukemia, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT06449482	—	P1/P2	terminated	Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Relapsed/Refractory AML (1)

NCT	Acronym	Phase	Status	Title
NCT05805072	AML	N/A	unknown	Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed and Refractory Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05530421	SELVEDge	P2	recruiting	Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Recurrent Glioblastoma, IDH-Wildtype (1)

NCT	Acronym	Phase	Status	Title
NCT05432804	—	P1/P2	recruiting	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)

NCT	Acronym	Phase	Status	Title
NCT05786989	—	P4	unknown	Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

AML, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT05736965	SAV	P2	recruiting	A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Peripheral T Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05675813	THEORY	P1/P2	recruiting	Genotype-guided Treatment in Newly Diagnosed PTCL

Relapsed or Refractory Acute Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05726110	—	P3	recruiting	Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT04756401	—	P2	active not recruiting	Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos (1)

NCT	Acronym	Phase	Status	Title
NCT05577364	—	P1/P2	unknown	Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

DLBCL (1)

NCT	Acronym	Phase	Status	Title
NCT05498636	—	P1/P2	unknown	SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Advanced Alveolar Soft Part Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT05333458	—	P2	recruiting	Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Double Hit Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05974085	—	P2	unknown	XPO-1 in Combination With RCHOP for DH/TH Lymphoma

DLBCL Germinal Center B-Cell Type (1)

NCT	Acronym	Phase	Status	Title
NCT05422066	—	P2	recruiting	Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Relapsed Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05170789	ESdRRMM	P2	withdrawn	Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05322330	—	P2	completed	Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Extramedullary Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05201118	CT103A	P1	unknown	A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Amyloid (1)

NCT	Acronym	Phase	Status	Title
NCT04984330	STARR	Early P1	withdrawn	Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

Myeloma Multiple (1)

NCT	Acronym	Phase	Status	Title
NCT04843579	ClaSPd	P2	terminated	Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Acute Leukemia of Ambiguous Lineage in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT04898894	—	P1	active not recruiting	Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05093608	—	P1	terminated	SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04854434	—	P2	terminated	A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Locally Advanced Unresectable or Metastatic Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04768881	—	P2	terminated	Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Recurrent Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT04764942	—	P1/P2	active not recruiting	Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Advanced Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04856189	—	P1/P2	terminated	Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Advance Solid Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT04850755	—	P1	completed	A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Advanced Refractory Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05035745	START	P1/P2	recruiting	Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recurrent Histiocytic and Dendritic Cell Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04640779	—	P1	completed	Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04534725	C-SMART	P3	completed	COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Liposarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03880123	—	P1	withdrawn	Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04607772	RR	P1/P2	withdrawn	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed/Refractory Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04442022	R-GDP	P2/P3	active not recruiting	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Gliosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT04216329	KPT-330	P1	active not recruiting	Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Multiple Myeloma, Refractory (1)

NCT	Acronym	Phase	Status	Title
NCT04414475	LDD	P2	recruiting	A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Glioblastoma Multiforme (1)

NCT	Acronym	Phase	Status	Title
NCT04421378	—	P1/P2	terminated	A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Non-Small Cell Lung Carcinoma (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT04256707	SPRINT	P1/P2	completed	Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Maximum Tolerated Dose (1)

NCT	Acronym	Phase	Status	Title
NCT04138381	SeliGIST	P1/P2	unknown	Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Primary Myelofibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT03627403	ESSENTIAL	P2	terminated	Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Relapsed Refractory Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT03732703	MyDRUG	P1/P2	completed	Myeloma-Developing Regimens Using Genomics (MyDRUG)

Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03095612	KPT-330	P1/P2	terminated	Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Untreated Adult Acute Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02835222	—	P2	active not recruiting	Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03147885	—	P1/P2	active not recruiting	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02741388	SELINDA	P1	completed	A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Peripheral T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03212937	KPT-330	P1	completed	Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

Dedifferentiated Liposarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT02606461	SEAL	P2/P3	completed	Selinexor in Advanced Liposarcoma

Myelodysplastic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT02431351	SIER	P2	withdrawn	Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

Recurrent Squamous Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02536495	—	P1/P2	withdrawn	Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02402764	KPT-330	P2	completed	Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02419495	KPT-330	P1	terminated	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Prolymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02303392	—	P1	completed	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02351505	—	P2	terminated	Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (1)

NCT	Acronym	Phase	Status	Title
NCT02299518	—	P1	completed	Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Colorectal Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02384850	SENTINEL	P1	terminated	Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer

Peripheral T-cell Lymphoma (PTCL) (1)

NCT	Acronym	Phase	Status	Title
NCT02314247	—	P2	terminated	Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Diabetic Foot Ulcers (1)

NCT	Acronym	Phase	Status	Title
NCT02367690	KPT-330	P1/P2	withdrawn	Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Rectal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02137356	—	P1	unknown	Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer

Esophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02283359	—	P1	terminated	Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Richter's Transformation (1)

NCT	Acronym	Phase	Status	Title
NCT02138786	SIRRT	P2	terminated	Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Acinar Cell Adenocarcinoma of the Pancreas (1)

NCT	Acronym	Phase	Status	Title
NCT02178436	—	P1/P2	completed	Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Solid Tumor Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT05177276	—	P1/P2	withdrawn	Selinexor Combination Ph 1 Study

Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02213133	STARRS	P2	terminated	Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Castration Levels of Testosterone (1)

NCT	Acronym	Phase	Status	Title
NCT02215161	—	P2	terminated	Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Carcinoma, Neuroendocrine (1)

NCT	Acronym	Phase	Status	Title
NCT02250885	—	P2	completed	KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Myelodysplastic Syndromes (1)

NCT	Acronym	Phase	Status	Title
NCT02228525	SINE	P2	completed	Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Recurrent Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT02120222	KPT-330	P1	completed	Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Salivary Gland Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02069730	—	N/A	completed	A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02146833	SHIP	P2	terminated	SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Ovarian Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02025985	SIGN	P2	completed	Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT01986348	KING	P2	terminated	Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01607905	—	P1	completed	Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Selinexor pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
SENTRY	NCT04562389	P3	active not recruiting	Myelofibrosis	353	PMID 39911057
XPORT-EC-042	NCT05611931	P3	active not recruiting	Endometrial Cancer	257	PMID 38627035
CERVINO	NCT06158841	P3	recruiting	Multiple Myeloma	380	—
BENCH	NCT04939142	P3	active not recruiting	Relapsed or Refractory Multiple Myeloma	150	—
ENGOT-EN5	NCT03555422	P3	completed	Endometrial Cancer	263	PMID 37669480
AlloRelapseMM	NCT05675319	P3	terminated	Multiple Myeloma	28	PMID 39865222
C-SMART	NCT04534725	P3	completed	Cancer	441	PMID 40874769
BOSTON	NCT03110562	P3	completed	Multiple Myeloma	402	PMID 34062004
SELVEDge	NCT05530421	P2	recruiting	Relapsed and Refractory Multiple Myeloma	33	—
SABLe	NCT04717700	P2	active not recruiting	Multiple Myeloma	50	—
Zillion	NCT07405255	P2	not yet recruiting	Central Nervous System Lymphoma	19	—
SENTRY-2	NCT05980806	P2	recruiting	Myelofibrosis	58	—
LDD	NCT04414475	P2	recruiting	Multiple Myeloma, Refractory	127	—
SAV	NCT05736965	P2	recruiting	AML, Adult	58	—
AVS	NCT05736978	P2	recruiting	AML	58	—
KPT-330	NCT02227251	P2	active not recruiting	Diffuse Large B-cell Lymphoma	244	PMID 33528286
SELIBORDARA	NCT03589222	P2	active not recruiting	Refractory Multiple Myeloma	62	—
SeliSarc	NCT06114004	P2	recruiting	Sarcoma,Soft Tissue	88	PMID 25305755
SPODUMENE	NCT05478993	P2	unknown	Multiple Myeloma	21	—
ESSENTIAL	NCT03627403	P2	terminated	Primary Myelofibrosis	17	—
AML	NCT05951855	P2	unknown	Acute Myeloid Leukemia (Relapsed/Refractory)	42	—
MUKtwelve	NCT06212596	P2	completed	Relapsed or Refractory Multiple Myeloma	66	—
ClaSPd	NCT04843579	P2	terminated	Myeloma Multiple	4	—
ESdRRMM	NCT05170789	P2	withdrawn	Relapsed Multiple Myeloma	0	PMID 28148715
SELECT	NCT03193437	P2	terminated	Thymoma	8	—
SINE	NCT02228525	P2	completed	Myelodysplastic Syndromes	25	PMID 32735836
Coronavirus	NCT04349098	P2	completed	Coronavirus Infection	190	—
TET-SEL	NCT03466827	P2	unknown	Thymoma	25	—
KING	NCT01986348	P2	terminated	Glioblastoma	76	—
STORM	NCT02336815	P2	completed	Multiple Myeloma	202	PMID 29381435
KPT-330	NCT02402764	P2	completed	Breast Cancer	10	PMID 30996012
SIER	NCT02431351	P2	withdrawn	Myelodysplastic Syndrome	0	—
AML	NCT02249091	P2	completed	Acute Myeloid Leukemia (Relapsed/Refractory)	42	—
SCORE	NCT02628704	P2	withdrawn	Multiple Myeloma	0	—
SOPRA	NCT02088541	P2	completed	Acute Myeloid Leukemia (AML)	317	PMID 34323164
SIGN	NCT02025985	P2	completed	Ovarian Carcinoma	116	PMID 31822399
SIRRT	NCT02138786	P2	terminated	Richter's Transformation	27	PMID 17242396
SHIP	NCT02146833	P2	terminated	Prostate Cancer	20	—
STARRS	NCT02213133	P2	terminated	Squamous Cell Carcinoma	45	—

Terminated and withdrawn Selinexor trials (36)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05952687withdrawnTrial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
NCT04661137suspendedA Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT05820763withdrawnSelinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06449482terminatedSelinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
NCT05675319terminatedAllogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT03627403terminatedSelinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
NCT02419495terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT04984330withdrawnSelinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
NCT04856189terminatedSelinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
NCT04768881terminatedSafety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT04421378terminatedA Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT03095612terminatedPhase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
NCT04843579terminatedTreatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
NCT05093608terminatedSELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
NCT04854434terminatedA Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT05170789withdrawnElotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT03193437terminatedSelinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
NCT03880123withdrawnSelinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
NCT04355676withdrawnEvaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
NCT01986348terminatedStudy Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT02431351withdrawnEfficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
NCT03071276terminatedSelinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT02628704withdrawnSelinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02215161terminatedSelinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
NCT02389543withdrawnStudy of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02384850terminatedPhase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
NCT02138786terminatedSelinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT02146833terminatedSHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT02351505terminatedSelinexor in Treating Patients With Relapsed Small Cell Lung Cancer
NCT02314247terminatedEfficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
NCT02283359terminatedSelinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
NCT02213133terminatedSelinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT02536495withdrawnSelinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
NCT02367690withdrawnStudy of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
NCT05177276withdrawnSelinexor Combination Ph 1 Study

All Selinexor trials (181)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06239272	NRSTS	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)	P1/P2	recruiting	139	St. Jude Children's Research Hospital	Mar 2024
NCT05952687		Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors	P1	withdrawn	0	St. Jude Children's Research Hospital	Mar 2024
NCT05983276		Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer	P2	recruiting	40	Loyola University	Nov 2023
NCT07574528		A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma	P2	not yet recruiting	47	Sun Yat-sen University	May 2026
NCT07200102		Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma	P1	recruiting	20	Washington University School of Medicine	Mar 2026
NCT07569757		Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma	P3	not yet recruiting	260	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Jun 2026
NCT07447817		Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias	P2	not yet recruiting	26	John Mascarenhas	May 2026
NCT05530421	SELVEDge	Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma	P2	recruiting	33	University of Miami	Mar 2023
NCT06744894		SIL as Maintenance Therapy in Multiple Myeloma	P2	not yet recruiting	50	Navy General Hospital, Beijing	Jan 2025
NCT07138209		A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma	P3	recruiting	228	Qilu Pharmaceutical Co., Ltd.	Nov 2025
NCT07276698		Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma	P2	not yet recruiting	39	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Dec 2025
NCT07191431	SELINA	A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）	N/A	recruiting	25	Ruijin Hospital	Sep 2025
NCT05985161		A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	P2	recruiting	45	Memorial Sloan Kettering Cancer Center	Aug 2023
NCT07479979		Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma	P1/P2	recruiting	62	Natalie Callander	Jul 2026
NCT07011056		A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma	P3	recruiting	390	Chengdu Zenitar Biomedical Technology Co., Ltd	Jul 2025
NCT04717700	SABLe	Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients	P2	active not recruiting	50	Ida Bruun Kristensen	Aug 2021
NCT07554482		Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma	P2	not yet recruiting	34	Beijing Tongren Hospital	May 2026
NCT05028348		A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma	P3	active not recruiting	117	European Myeloma Network B.V.	Apr 2022
NCT07579234		A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma	P3	recruiting	261	Shandong New Time Pharmaceutical Co., LTD	Jan 2026
NCT07172412		Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer	P2	not yet recruiting	165	Tianjin Medical University Cancer Institute and Hospital	Nov 2025
NCT07002099		Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study	P2	recruiting	26	Second Affiliated Hospital of Soochow University	Jun 2025
NCT07405255	Zillion	Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma	P2	not yet recruiting	19	Ruijin Hospital	Jan 2026
NCT07094464		Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation	P1	active not recruiting	20	Daihong Liu	Jun 2025
NCT06552559	SIENA	Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	P1/P2	recruiting	37	Samsung Medical Center	May 2024
NCT06652139		Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive	P2	not yet recruiting	82	Ruijin Hospital	Nov 2024
NCT05980806	SENTRY-2	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia	P2	recruiting	58	Karyopharm Therapeutics Inc	Apr 2024
NCT06556199		A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma	P1/P2	recruiting	38	Second Affiliated Hospital, School of Medicine, Zhejiang University	Aug 2024
NCT04216329	KPT-330	Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma	P1	active not recruiting	11	National Cancer Institute (NCI)	Jul 2020
NCT05675813	THEORY	Genotype-guided Treatment in Newly Diagnosed PTCL	P1/P2	recruiting	264	Ruijin Hospital	Feb 2023
NCT06452446	Selinexor	Telehealth-based Symptom Management for Veterans Treated With Selinexor	—	active not recruiting	20	Durham VA Medical Center	Sep 2024
NCT06966154		A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	P1/P2	recruiting	68	Fudan University	May 2025
NCT06517511		Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)	P2	recruiting	42	Sun Yat-sen University	Aug 2024
NCT04562389	SENTRY	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis	P3	active not recruiting	353	Karyopharm Therapeutics Inc	Mar 2021
NCT06813079		Using Tumor Models to Determine Treatments	P2	not yet recruiting	25	University Health Network, Toronto	Feb 2025
NCT05611931	XPORT-EC-042	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	P3	active not recruiting	257	Karyopharm Therapeutics Inc	Apr 2023
NCT04414475	LDD	A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.	P2	recruiting	127	Karyopharm Therapeutics Inc	Jul 2020
NCT07369739		Golidocitinib Combined With Selinexor for CAEBVD	P2/P3	recruiting	28	Beijing Friendship Hospital	Jan 2026
NCT06765928		Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT	P2	not yet recruiting	73	Ruijin Hospital	Jan 2025
NCT06822972		HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM	P2	recruiting	27	Duke University	Aug 2025
NCT06158841	CERVINO	Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma	P3	recruiting	380	AbbVie	May 2024
NCT07437170		Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML	P2	active not recruiting	10	The Children's Hospital of Zhejiang University School of Medicine	Jan 2024
NCT03147885		Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	P1/P2	active not recruiting	43	Barbara Ann Karmanos Cancer Institute	Jun 2017
NCT04756401		Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma	P2	active not recruiting	52	Academic and Community Cancer Research United	Dec 2022
NCT04764942		Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	P1/P2	active not recruiting	39	Mayo Clinic	May 2021
NCT05035745	START	Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)	P1/P2	recruiting	63	National University Hospital, Singapore	Mar 2021
NCT06613035		Twice-per-weekSelinexor, 2 Days Melphalan	P3	not yet recruiting	126	Institute of Hematology & Blood Diseases Hospital, China	Sep 2024
NCT04898894		Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia	P1	active not recruiting	37	St. Jude Children's Research Hospital	Nov 2021
NCT07204041		Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH	P2	active not recruiting	40	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Aug 2025
NCT06573151		Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL	P2	not yet recruiting	28	Ruijin Hospital	Sep 2024
NCT06573138		Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL	P2	not yet recruiting	18	Ruijin Hospital	Sep 2024
NCT05432804		Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	P1/P2	recruiting	97	National Cancer Institute (NCI)	Mar 2023
NCT05099003	DIPG	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	P1/P2	recruiting	132	National Cancer Institute (NCI)	May 2022
NCT06225310	KPT-IST-391	A Trial of Selinexor, Ruxolitinib and Methylprednisolone	P1	recruiting	30	Oncotherapeutics	Aug 2024
NCT05333458		Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial	P2	recruiting	27	National Cancer Institute (NCI)	Aug 2022
NCT07514052		Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study	—	recruiting	127	Shanxi Bethune Hospital	Jan 2026
NCT05736965	SAV	A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia	P2	recruiting	58	Shanghai Tong Ren Hospital	Feb 2023
NCT02343042	STOMP	Selinexor and Backbone Treatments of Multiple Myeloma Patients	P1/P2	active not recruiting	300	Karyopharm Therapeutics Inc	Oct 2015
NCT05736978	AVS	Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results	P2	recruiting	58	Shanghai Tong Ren Hospital	Mar 2023
NCT06853678		Second-line Immunotherapy for ES-SCLC	N/A	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	Feb 2025
NCT04661137		A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma	P2	suspended	96	Hackensack Meridian Health	Mar 2021
NCT02835222		Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients	P2	active not recruiting	57	Wake Forest University Health Sciences	Feb 2018
NCT05820763		Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant	P2	withdrawn	0	Washington University School of Medicine	Jan 2024
NCT06559553	Selinexor	"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL	P1/P2	recruiting	50	Mingzhi Zhang	Sep 2024
NCT05698147		Selinexor in Combination With MTX+Ritu to Treat R/R CNSL	P1/P2	recruiting	30	Tong Chen, MD	Aug 2023
NCT04442022	R-GDP	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	P2/P3	active not recruiting	501	Karyopharm Therapeutics Inc	Sep 2020
NCT02436707		Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma	P2	active not recruiting	129	Canadian Cancer Trials Group	Oct 2015
NCT02227251	KPT-330	Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	P2	active not recruiting	244	Karyopharm Therapeutics Inc	Nov 2014
NCT04925193		Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma	P2	active not recruiting	18	University of Colorado, Denver	Nov 2021
NCT06900088		Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients	P2	not yet recruiting	20	Institute of Hematology & Blood Diseases Hospital, China	Apr 2025
NCT05954780	SEATTLE	Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma	—	active not recruiting	75	iOMEDICO AG	Jun 2023
NCT06664970		A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor	P2	enrolling by invitation	39	Peking Union Medical College Hospital	Nov 2024
NCT06169215		Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma	P2	active not recruiting	70	National Cancer Institute (NCI)	Jul 2024
NCT04562870		A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis	P2	active not recruiting	112	Karyopharm Therapeutics Inc	Mar 2021
NCT03589222	SELIBORDARA	SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma	P2	active not recruiting	62	PETHEMA Foundation	Jul 2018
NCT06265545		Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia	N/A	recruiting	120	Institute of Hematology & Blood Diseases Hospital, China	Feb 2024
NCT06114004	SeliSarc	Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)	P2	recruiting	88	Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas	Sep 2023
NCT04782687		Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	P2	active not recruiting	73	US Oncology Research	Sep 2021
NCT04595994	SeliSarc	Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma	P1	unknown	14	Grupo Espanol de Investigacion en Sarcomas	Sep 2020
NCT05577364		Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients	P1/P2	unknown	54	Sun Yat-sen University	Nov 2022
NCT05597345		Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma	P2	recruiting	15	University of Rochester	Aug 2023
NCT05498636		SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression	P1/P2	unknown	67	The Affiliated Hospital of Qingdao University	Oct 2022
NCT05422066		Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma	P2	recruiting	50	Li Zhiming	Jul 2022
NCT05422027		Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma	P1/P2	recruiting	42	Xia Zhongjun	Jul 2022
NCT04939142	BENCH	A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)	P3	active not recruiting	150	Antengene Corporation	Jul 2021
NCT04607772	RR	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	P1/P2	withdrawn	0	Karyopharm Therapeutics Inc	Nov 2020
NCT04941937		Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM	P2	unknown	90	Juan Du	Jan 2022
NCT04640779		Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	P1	completed	22	Mayo Clinic	Feb 2021
NCT02199665	SINE	Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	P1	completed	52	University of Chicago	Jun 2014
NCT05852028		A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma	—	unknown	250	Ruijin Hospital	Dec 2022
NCT07215832	KEAP	Karyopharm Expanded Access Program for Selinexor	—	available	0	Karyopharm Therapeutics Inc	—
NCT05900882		SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease	P2	recruiting	35	The First Affiliated Hospital with Nanjing Medical University	Jul 2022
NCT05478993	SPODUMENE	Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement	P2	unknown	21	Peking University People's Hospital	Oct 2022
NCT05923879		Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma	—	unknown	30	Ruijin Hospital	Jun 2023
NCT05822050		An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL	P2/P3	unknown	20	The First Hospital of Jilin University	Jun 2023
NCT04811196		A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients	P1	completed	56	University Health Network, Toronto	Mar 2021
NCT03555422	ENGOT-EN5	Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]	P3	completed	263	Karyopharm Therapeutics Inc	Jan 2018
NCT06449482		Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy	P1/P2	terminated	6	Institute of Hematology & Blood Diseases Hospital, China	May 2023
NCT05675319	AlloRelapseMM	Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy	P3	terminated	28	Universitätsklinikum Hamburg-Eppendorf	Mar 2023
NCT04850755		A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies	P1	completed	11	National University Hospital, Singapore	Mar 2021
NCT03627403	ESSENTIAL	Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors	P2	terminated	17	University of Utah	May 2019
NCT05951855	AML	Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients	P2	unknown	42	The First Affiliated Hospital of Soochow University	Mar 2023
NCT05726110		Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia	P3	recruiting	50	Shanxi Bethune Hospital	Jan 2023
NCT03732703	MyDRUG	Myeloma-Developing Regimens Using Genomics (MyDRUG)	P1/P2	completed	103	Multiple Myeloma Research Consortium	Apr 2019
NCT02323880		Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	P1	completed	59	Children's Oncology Group	Oct 2015
NCT04891744		Selinexor in Combination With Thalidomide and Dexamethasone in RRMM	P1/P2	unknown	48	Li Zheng	Jul 2021
NCT04877275		ATG-010(Selinexor) in Combination With Chemotherapy in RRMM	P2	unknown	50	Chunyan Sun, MD	May 2021
NCT05786989		Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma	P4	unknown	32	Chongqing University Cancer Hospital	Feb 2023
NCT02419495	KPT-330	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	P1	terminated	221	M.D. Anderson Cancer Center	Jun 2015
NCT03955783		Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies	P1	completed	78	Sanjay Mohan	Jun 2019
NCT04256707	SPRINT	Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment	P1/P2	completed	126	Karyopharm Therapeutics Inc	Jan 2020
NCT05805072	AML	Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients	N/A	unknown	20	The First Affiliated Hospital of Soochow University	May 2023
NCT04984330	STARR	Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease	Early P1	withdrawn	0	Weill Medical College of Cornell University	Dec 2021
NCT05975944		Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer	P1/P2	unknown	49	Tianjin Medical University Cancer Institute and Hospital	Sep 2023
NCT05974085		XPO-1 in Combination With RCHOP for DH/TH Lymphoma	P2	unknown	10	Zhejiang Cancer Hospital	Aug 2022
NCT04856189		Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma	P1/P2	terminated	4	Mamta Parikh	Apr 2021
NCT05322330		Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma	P2	completed	20	The First Affiliated Hospital of Soochow University	Feb 2022
NCT05201118	CT103A	A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma	P1	unknown	20	Chunrui Li	Jan 2022
NCT04519476		Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.	P1	unknown	22	Oncotherapeutics	Nov 2020
NCT06212596	MUKtwelve	Selinexor, Cyclophosphamide and Prednisone in Myeloma	P2	completed	66	University of Leeds	Jul 2018
NCT04768881		Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma	P2	terminated	15	Karyopharm Therapeutics Inc	May 2021
NCT04421378		A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma	P1/P2	terminated	74	Karyopharm Therapeutics Inc	Jun 2020
NCT02069730		A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	N/A	completed	114	University Health Network, Toronto	Jun 2014
NCT04534725	C-SMART	COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;	P3	completed	441	Peter MacCallum Cancer Centre, Australia	Dec 2020
NCT04138381	SeliGIST	Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)	P1/P2	unknown	30	Grupo Espanol de Investigacion en Sarcomas	Aug 2019
NCT02178436		Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer	P1/P2	completed	15	Mohammed Najeeb Al Hallak	Oct 2014
NCT03095612	KPT-330	Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)	P1/P2	terminated	41	University of Texas Southwestern Medical Center	Mar 2018
NCT04843579	ClaSPd	Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients	P2	terminated	4	Weill Medical College of Cornell University	Dec 2021
NCT05093608		SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma	P1	terminated	2	H. Lee Moffitt Cancer Center and Research Institute	Nov 2021
NCT04854434		A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations	P2	terminated	13	Karyopharm Therapeutics Inc	Jun 2021
NCT03110562	BOSTON	Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma	P3	completed	402	Karyopharm Therapeutics Inc	May 2017
NCT05170789	ESdRRMM	Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma	P2	withdrawn	0	Tulane University School of Medicine	Apr 2022
NCT02303392		Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	P1	completed	34	Jennifer Woyach	Jun 2015
NCT03193437	SELECT	Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy	P2	terminated	8	Georgetown University	Apr 2018
NCT02606461	SEAL	Selinexor in Advanced Liposarcoma	P2/P3	completed	342	Karyopharm Therapeutics Inc	Jan 2016
NCT02741388	SELINDA	A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP	P1	completed	39	The Lymphoma Academic Research Organisation	Oct 2016
NCT03042819		Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas	P1	completed	25	University Health Network, Toronto	May 2017
NCT02269293	KPT-330	Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers	P1	completed	23	Memorial Sloan Kettering Cancer Center	Oct 2014
NCT02228525	SINE	Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes	P2	completed	25	Memorial Sloan Kettering Cancer Center	Aug 2014
NCT02780609	HDM	Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma	P1/P2	completed	22	H. Lee Moffitt Cancer Center and Research Institute	Jul 2017
NCT02403310		A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML	P1	completed	21	H. Lee Moffitt Cancer Center and Research Institute	Jun 2015
NCT03212937	KPT-330	Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma	P1	completed	11	National Cancer Centre, Singapore	Jul 2016
NCT03880123		Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	P1	withdrawn	0	Matthew Ingham	Nov 2020
NCT02831686	KPT-330	A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma	P1	completed	18	Memorial Sloan Kettering Cancer Center	Jul 2016
NCT04349098	Coronavirus	Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection	P2	completed	190	Karyopharm Therapeutics Inc	Apr 2020
NCT04355676		Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19	P2	withdrawn	0	Karyopharm Therapeutics Inc	Apr 2020
NCT02485535		Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	P1	completed	12	University of Chicago	Sep 2015
NCT03466827	TET-SEL	Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma	P2	unknown	25	Morten Mau-Soerensen	Oct 2017
NCT01986348	KING	Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas	P2	terminated	76	Karyopharm Therapeutics Inc	Mar 2014
NCT03661515	FLAGINEXOR	Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML	P1	completed	16	PETHEMA Foundation	Jul 2018
NCT02336815	STORM	Selinexor Treatment of Refractory Myeloma	P2	completed	202	Karyopharm Therapeutics Inc	May 2015
NCT02416908		Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia	P1/P2	completed	40	Washington University School of Medicine	Jun 2015
NCT02402764	KPT-330	Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)	P2	completed	10	H. Lee Moffitt Cancer Center and Research Institute	Jul 2015
NCT02431351	SIER	Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients	P2	withdrawn	0	Karyopharm Therapeutics Inc	Nov 2015
NCT02573363		Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia	P1	completed	25	University of Chicago	Oct 2015
NCT03071276		Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia	P2	terminated	37	St. Jude Children's Research Hospital	Jan 2016
NCT02530476	SINE	Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia	P1/P2	completed	17	M.D. Anderson Cancer Center	Dec 2015
NCT03850704		Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma	—	no longer available	0	Masonic Cancer Center, University of Minnesota	—
NCT02249091	AML	A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)	P2	completed	42	GSO Global Clinical Research BV	Sep 2014
NCT02628704	SCORE	Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma	P2	withdrawn	0	Karyopharm Therapeutics Inc	Dec 2015
NCT02120222	KPT-330	Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery	P1	completed	8	Kari Kendra	Aug 2014
NCT02215161		Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer	P2	terminated	14	University of California, San Francisco	Sep 2014
NCT02186834	KPT-330	Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma	P1/P2	completed	28	H. Lee Moffitt Cancer Center and Research Institute	Sep 2014
NCT02299518		Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	completed	23	Alice Mims	May 2015
NCT02389543	SLAM	Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients	P1/P2	withdrawn	0	Karyopharm Therapeutics Inc	Jul 2015
NCT02088541	SOPRA	Selinexor (KPT-330) in Older Patients With Relapsed AML	P2	completed	317	Karyopharm Therapeutics Inc	Mar 2014
NCT02137356		Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer	P1	unknown	28	Sheba Medical Center	Dec 2014
NCT02025985	SIGN	Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies	P2	completed	116	Karyopharm Therapeutics Inc	Apr 2014
NCT02384850	SENTINEL	Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer	P1	terminated	10	GSO Global Clinical Research BV	Mar 2015
NCT02093403		Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	completed	25	Bhavana Bhatnagar	Mar 2014
NCT02138786	SIRRT	Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation	P2	terminated	27	Karyopharm Therapeutics Inc	Nov 2014
NCT02250885		KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors	P2	completed	14	Gabrail Cancer Center Research	Aug 2014
NCT02146833	SHIP	SHIP (Selinexor in Hormone Insensitive Prostate Cancer)	P2	terminated	20	Karyopharm Therapeutics Inc	May 2014
NCT02351505		Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer	P2	terminated	1	Erin Bertino	May 2015
NCT01607905		Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer	P1	completed	192	Karyopharm Therapeutics Inc	Jun 2012
NCT02314247		Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma	P2	terminated	16	Karyopharm Therapeutics Inc	Feb 2015
NCT02283359		Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus	P1	terminated	3	H. Lee Moffitt Cancer Center and Research Institute	Dec 2014
NCT02212561		Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome	P1	completed	19	St. Jude Children's Research Hospital	Aug 2014
NCT02213133	STARRS	Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas	P2	terminated	45	Karyopharm Therapeutics Inc	Sep 2014
NCT02536495		Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer	P1/P2	withdrawn	0	Erin Bertino	Sep 2015
NCT02367690	KPT-330	Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients	P1/P2	withdrawn	0	Karyopharm Therapeutics Inc	Jan 2015
NCT05177276		Selinexor Combination Ph 1 Study	P1/P2	withdrawn	0	Martin Gutierrez	Sep 2014

Selinexor clinical trials: frequently asked questions

How many Selinexor clinical trials are there?: 181 Selinexor clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 43 are marked completed.
Are Selinexor clinical trials recruiting in 2026?: Yes — 40 Selinexor trials are actively recruiting in 2026, with 226 U.S. sites across 42 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Selinexor being studied for?: Selinexor is being studied for Multiple Myeloma, Acute Myeloid Leukemia, Refractory Multiple Myeloma, Myelofibrosis, Endometrial Cancer and 281 more. The trials are grouped by indication on this page.
What phase is Selinexor in?: Selinexor clinical trials span 1 Phase 4, 15 Phase 3, 76 Phase 2, 36 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Selinexor clinical trials?: The lead sponsor across the most Selinexor trials is Karyopharm Therapeutics Inc, with 98 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Selinexoras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Selinexor overview Selinexor evidence & publications